Biotech IPO market reopens for mature pipelines
The biotech sector is entering a multi-year recovery driven by IPO activity for mid-to-late stage assets and urgent big pharma M&A needs.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.